Media coverage about GenMark Diagnostics (NASDAQ:GNMK) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GenMark Diagnostics earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.8084316993639 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
GenMark Diagnostics traded down $0.04, reaching $6.75, during midday trading on Friday, Marketbeat.com reports. The stock had a trading volume of 123,109 shares, compared to its average volume of 195,495. GenMark Diagnostics has a 1-year low of $3.63 and a 1-year high of $12.55. The company has a current ratio of 2.79, a quick ratio of 2.45 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $374.03 million, a PE ratio of -5.58 and a beta of 0.47.
Get GenMark Diagnostics alerts:GenMark Diagnostics (NASDAQ:GNMK) last posted its earnings results on Tuesday, May 1st. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. GenMark Diagnostics had a negative net margin of 97.90% and a negative return on equity of 77.35%. The business had revenue of $20.65 million for the quarter, compared to analyst estimates of $17.12 million. analysts anticipate that GenMark Diagnostics will post -0.78 EPS for the current fiscal year.
GNMK has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of GenMark Diagnostics in a research note on Tuesday, April 24th. BidaskClub lowered shares of GenMark Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th. BTIG Research set a $11.00 price target on shares of GenMark Diagnostics and gave the stock a “buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research lowered shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Canaccord Genuity increased their price target on shares of GenMark Diagnostics from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, June 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $10.80.
In other GenMark Diagnostics news, SVP Eric Stier sold 10,000 shares of the firm’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $6.92, for a total value of $69,200.00. Following the sale, the senior vice president now directly owns 187,173 shares in the company, valued at approximately $1,295,237.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Hany Massarany sold 4,168 shares of the firm’s stock in a transaction on Wednesday, May 23rd. The stock was sold at an average price of $6.88, for a total transaction of $28,675.84. Following the completion of the sale, the insider now owns 694,208 shares in the company, valued at $4,776,151.04. The disclosure for this sale can be found here. Insiders sold a total of 53,830 shares of company stock worth $369,572 over the last quarter. 7.50% of the stock is currently owned by company insiders.
About GenMark Diagnostics
GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
Featured Article: How do investors use RSI to grade stocks?
No comments:
Post a Comment